Entrepreneurial Scientific Leader and Inventor
During his 20+ year tenure at Intrexon, Dr. Reed pioneered technologies to improve the safety and efficacy of gene and cell therapies. He gained multidisciplinary expertise that enabled advanced technology acquisitions to complement Intrexon’s in-house portfolio and stewarded the growth of commercial operations and business development, including strategic ventures in health, food, environment and consumer sectors.
Dr. Reed architected the genetic platform, as well as, therapeutic candidates for oncology, cardiovascular, and rare disease treatments now advancing in the clinic. Prior to founding Intrexon, Dr. Reed’s scientific training focused on characterizing the structure and function of genes critical for cardiovascular development and pathophysiology.
University of Cincinnati (1999)
Wright State University (1991)
University of California, Davis (1989)
Founder & President (2020)
BSD’s leadership has multi-decade experience learning to balance the promise vs reality of employing technologies that meet safety, efficacy, COGS, and consumer acceptance requirements. BSD’s core mission links intellectual property with the scientific and business perspectives required for new product development integrating bioinformatics, synthetic biology, and device engineering disciplines. Employing these synergistic areas of expertise, the BSD team focuses on inventing complex, novel products to meet long-standing market needs.
In 2020, Intrexon changed its name to Precigen, Inc. to reflect its refocused effort on healthcare to address unmet medical needs across a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine.
Intrexon focused on bioengineering solutions for health, food, energy, environment and consumer sectors with numerous first-in-class products trailblazing regulatory paths to market.
Highlights & Accomplishments
Founded DNA-based startup company in 1998 to address commercial opportunities for genomics-based molecular tool technologies and therapeutic products. Secured combined raises of in excess of $100 million USD as private company prior to IPO supporting acquisition and expansion of platform technology applications for development of health, food, energy, environment, and consumer products.
Initiated and Co-led early development of the UltraPorator® gene delivery system approved by FDA for use in autologous chimeric antigen receptor T cell (UltraCAR-T®) clinical trials.
Founded BioSolution Designs (BSD) in 2020 to advance new venture opportunities spanning genomics applications across sectors. BSD’s core mission links intellectual property with the scientific and business perspectives required for new product development integrating bioinformatics, synthetic biology, and biomaterial engineering disciplines.
Granted Patents & Active Patent Applications
Therapeutic Inhibitors of PAI-1 Function and Methods of Their Use
Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules and Uses Thereof
Modulating Expression of Polypeptides via New Gene Switch Expression Systems
Triple-Gene presents interim clinical data for INXN-4001 Triple Effector Cardiac Gene Therapy
Invited panelist for Council on Competitiveness Briefing to accompany release of “Report on Future of Bioscience and Manufacturing”
Invited presenter and panelist for National Academies of Sciences, Engineering, and Medicine Committee on Future Biotechnology Products and Opportunities to Enhance Capabilities of the Biotechnology Regulatory System
Targeted Inhibition of Ca2+/Calmodulin Dependent Protein Kinase II in Cardiac Longitudinal Sarcoplasmic Reticulum Results in Decreased Phospholamban Phosphorylation at Threonine-17
Structure and Organization of the Mouse ATP2A2 Gene Encoding the Sarco(endo)-plasmic Reticulum Ca2+-ATPase 2 (SERCA2) Isoforms
Impaired Cardiac Performance in Heterozygous Mice with a Null Mutation in Sarco(endo)plasmic Reticulum Ca2+-ATPase Isoform 2 (SERCA2) Gene
Generation of Mice with a Conditional Allele for the Transforming Growth Factor Beta3 Gene. Thomas Doetschman, Teodora Georgieva, Hongqi Li, Thomas D. Reed, Christina Grisham, Jacqueline Friel, Mark A. Estabrook, Connie Gard, L.P. Sanford, and Mohamad Azhar. Genesis. 2012 January; 50(1):59-66.
ERK Regulates Strain-Induced Migration and Proliferation from Different Subcellular Locations. Gayer CP, Craig DH, Flanagan TL, Reed TD, Cress DE, Basson MD. Journal of Cellular Biochemistry. (2010) March; 109(4):711-25.
Targeted Inhibition of Ca2+/Calmodulin Dependent Protein Kinase II in Cardiac Longitudinal Sarcoplasmic Reticulum Results in Decreased Phospholamban Phosphorylation at Threonine-17. Ji Yong, Bailing Li, Thomas Reed, John Lorenz and John Dedman. Journal of Biological Chemistry. (2003) 278:25063-71.
Replacement of the Muscle-Specific Sarcoplasmic Reticulum Ca(2+)-ATPase Isoform SERCA2a by the Nonmuscle SERCA2b Homologue Causes Mild Concentric Hypertrophy and Impairs Contraction-Relaxation of the Heart. Ver Heyen M, Heymans S, Antoons G, Reed T, Periasamy M, Awede B, Lebacq J, Vangheluwe P, Dewechin M, Collen deS, Sipido K, Carmeliet P, Wuytack F. Circulation Research (2001) 89:838-46.
Changes in Ionic Currents and Beta-Adrenergic Receptor Signaling in Hypertrophied Myocytes Overexpressing G alpha(q). Mitari S, Reed TD and Yatani A. American Journal of Physiology. (2000) 279:H139-48.
The Expression of SR Calcium ATPase and the Na+/Ca2+ Exchanger are Antithetically Regulated during Mouse Cardiac Development and in Hypo/Hyperthyroidism. Reed TD, Babu GJ, Ji Y, Zilberman A, Ver Heyen M, Wuytack F, Periasamy M. Journal of Molecular and Cellular Cardiology. (2000) 32:453-64.
Impaired Cardiac Performance in Heterozygous Mice with a Null Mutation in Sarco(endo)plasmic Reticulum Ca2+-ATPase Isoform 2 (SERCA2) Gene. Periasamy M, Reed TD, Liu LH, Ji Y, Loukianov E, Paul RI, Nieman ML, Miller ML, Riddle T, Duffy JJ, Doetschman, T, Lorenz JN and Shull GE. Journal of Biological Chemistry (1999) 274:2556-62.
Targeted Overexpression of the Sarcoplasmic Reticulum Ca2+-ATPase Increases Cardiac Contractility in Transgenic Mouse Hearts. Baker DL, Hashimoto K, Grupp IL, Ji Y, Reed T, Loukianov E, Grupp G, Bhagwat A, Hoit B, Walsh R, Marban E and Periasamy M. Circulation Research (1998) 83:1205-14.
Sarco(endo)plasmic Reticulum Ca2+ ATPase Isoforms and Their Role in Muscle Physiology and Pathology. Loukianov E, Ji Y, Baker DL, Reed T, Babu J, Loukianov T, Greene A, Shull G and Periasamy M. Annals of the New York Academy of Sciences (1998) 853:251-59.
A Novel E Box/AT-Rich Element is Required for Muscle-Specific Expression of the Sarcoplasmic Reticulum Ca2+-ATPase (SERCA2) Gene. Baker DL, Dave V, Reed T, Misra S and Periasamy M. Nucleic Acids Research (1998) 26:1092-98.
Multiple Sp1 Binding Sites in the Cardiac/Slow Twitch Muscle Sarcoplasmic Reticulum Ca2+-ATPase Gene Promoter are Required for Expression in Sol8 Muscle Cells. Baker D, Dave V, Reed T and Periasamy M. Journal of Biological Chemistry (1996) 271:5921-28.
Characterization of the Mouse Cardiac/Slow-Twitch Muscle-Enhanced Sarco(endo)plasmic Reticulum Calcium ATPase (SERCA2) Gene. Thomas D. Reed. Doctor of Philosophy Dissertation (1998) University of Cincinnati College of Medicine; Cincinnati, Ohio.
A GTP-binding Activity from Bovine Heart Affects Phosphoinositide-Specific Phospholipase C (PIC) Activity. Thomas D. Reed. Master of Science Thesis (1991) Wright State University; Dayton, Ohio.
Safety of First-in-Human Triple Gene Therapy for Heart Failure Patients
Ewa Jaruga-Killeen, David Bull, Kapildeo Lotun, Timothy Henry, Gregory Egnaczyk, Thomas Reed, Amit Patel. American Heart Association, Scientific Sessions 2019.
Regulated Intratumoral Expression of IL-12 in Combination with Cytotoxic Agents as a Strategy for the Treatment of Metastatic Breast Cancer
John Nemunaitis, Heather McArthur, Clifford Hudis, Thomas Reed, Samuel Broder, Francois Lebel, John Barrett, Jonathan Lewis, Larry Norton. San Antonio Breast Cancer Symposium 2013.
Regulated Immunodulators Expression Using the RheoSwitch Therapeutic System® Platform in Human Mesenchymal Stem Cells
T. Chan, A. Prabhu, A. Elayadi, L. Williams, V. Dailey, K. Elliot, T.S Snipas, J. Carson, J. Lewis, S. Schauer, R. Einstein, J. Rieger, L Humeau and T. Reed. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013.
Safety of First-in-Human Triple Gene Therapy for Heart Failure Patients. Ewa Jaruga-Killeen, David Bull, Kapildeo Lotun, Timothy Henry, Gregory Egnaczyk, Thomas Reed, Amit Patel. American Heart Association, Scientific Sessions 2019.
Human Cardiac iPSC Evaluation of Novel Triple Effector Gene Therapy for Dilated Cardiomyopathy. Dimki Patel, Joseph Wu, Thomas Reed, Amit Patel. American Society of Gene and Cell Therapy, Annual Meeting 2019.
Minimally Invasive Novel Triple Effector Gene Therapy for Adriamycin Cardiomyopathy. Paul Grayburn, Dimki Patel, Shuyuan Chen, Thomas Reed, Amit Patel. American Society of Gene and Cell Therapy, Annual Meeting 2019.
Retrograde Delivery of Novel Triple Effector pDNA Gene Therapy for Heart Failure. Thomas Reed, Dimki Patel, Eric Rodenberg, Brad Shirley, Mark Johnson, Amit Patel. American Society of Gene and Cell Therapy, Annual Meeting 2019.
First Human Experience with Novel Triple Effector Gene Therapy for Heart Failure – INXN-4001. Thomas Reed, Amy Lankford, David Bull, Ewa Jaruga-Killeen, Amit Patel. American Society of Gene and Cell Therapy, Annual Meeting 2019.
Ad-RTS-hIL-12 + Veledimex Regulation of IL-12 Expression in Advanced Breast Cancer and Melanoma. John Nemunaitis, Gerald Linette, Haythem Ali, Troy Guthrie, Francois Lebel, John Barrett, Thomas Reed, Suma Krishnan, Jonathan Lewis, Larry Norton. AACR Tumor Immunology 2014.
Pharmacodynamics and Functionality of RheoSwitch® Regulated Immunostimulatory and Immunomodulatory Proteins, Expressed from a Multigenic Embedded Cellular Bioreactor following Intramuscular Electroporation in Mice. Pooja Agarwal, Stephen Schauer, Xiaohong Ma, Jacques Plummer, Tim Chan, Lindsay Williams, M. Kaloss, John Barrett, R. Einstein, Laurent Humeau and Thomas Reed. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013.
Integration of a Modularized Protein Engineering Technology and the RheoSwitch Therapeutic System® (RTS®) Platform to Develop High Affinity Trastuzumab Single Chain Variable Fragment-Fc Proteins for Gene Therapy Applications. C. Reed, V. Dailey, A. Elayadi, L. Williams, D. Schneider, T. Reed, J. Lewis, R. Einstein and S. Broder. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013.
Regulated Immunodulators Expression Using the RheoSwitch Therapeutic System® Platform in Human Mesenchymal Stem Cells. T. Chan, A. Prabhu, A. Elayadi, L. Williams, V. Dailey, K. Elliot, T.S Snipas, J. Carson, J. Lewis, S. Schauer, R. Einstein, J. Rieger, L Humeau and T. Reed. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013.
Public and Community Service
U.S. Council on Competitiveness Technology Leadership & Strategy Initiative Committee
Wright State University Contributor
Christ’s Community in College Hill, Trustee, Chairperson
U.S. Council on Competitiveness Technology Leadership & Strategy Initiative Committee (2016-19). The TLSI is a cross-sectoral, results-driven “action tank” making the business case for strategic, prioritized investments in the research, talent and infrastructure necessary for tech-based innovation; chaired by Boeing Chief Technology Officer Greg Hyslop, Lockheed Martin CTO Keoki Jackson and Deere & Company VP for Advanced Technology & Engineering Klaus Hoehn and comprising a peer group of CTOs, CSOs and heads of research at leading companies, universities and national laboratories. Click here to learn more about TLSI mission.
Wright State University Contributor
- Co-sponsored development of the College of Liberal Arts’ (COLA) “Change the World”
- Co-sponsored entrepreneurial programs led by the College of Science and Mathematics (COSM)
- Co-sponsored collaborative initiative between COSM and COLA’s Departments of Theatre, Dance, and Motion Pictures focused on empowering incoming freshmen
Cincinnati Life Science CEO Roundtable Member (2002-04)
Cincinnati Chamber of Commerce, Regional Entrepreneurial Network, “Voice of the Consumer” High-tech Leadership Committee Member (2002)
Policy Steering Committee Advisor, Chris Monzel for Cincinnati City Council Campaign (2000)